Logo

PharmaShots Weekly Snapshots (August 8 - 12, 2022)

Share this

PharmaShots Weekly Snapshots (August 8 - 12, 2022)

Pfizer Reports Results of 20vPnC in P-III Trial for the Prevention of Invasive Pneumococcal Disease

Published: Aug 12, 2022 | Tags: Pfizer, 20vPnC, Invasive Pneumococcal Disease, Clinical Trial, P-III

Daiichi Sankyo and AstraZeneca’s Enhertu Receives the US FDA’s Approval for the Treatment of HER2 Mutant Metastatic Non-Small Cell Lung Cancer

Published: Aug 12, 2022 | Tags: Daiichi Sankyo, AstraZeneca, Enhertu, HER2 Mutant Metastatic Non-Small Cell Lung Cancer, Regulatory, US, FDA, P-II, DESTINY-Lung02

Argenx’s Vyvgart Receives the EC’s Approval for the Treatment of Generalized Myasthenia Gravis

Published: Aug 12, 2022 | Tags: Argenx, Vyvgart, Generalized Myasthenia Gravis, Regulatory, EU, US, FDA, Japan, China, Canada, P-III, ADAPT

BridgeBio, Sentynl, and Medison Reports the Approval of Nulibry in Israel for the Treatment of Molybdenum Cofactor Deficiency Type A

Published: Aug 12, 2022 | Tags: BridgeBio, Sentynl, Medison, Nulibry, Molybdenum Cofactor Deficiency Type A, Regulatory, US, FDA, EMA, CHMP

Abbott Reports Study Results Evaluating the i-STAT TBI Plasma Test for the Prediction of the Outcomes Due to Brain Injury

Published: Aug 12, 2022 | Tags: Abbott, i-STAT TBI Plasma Test, Brain Injury, Clinical Trial, US, FDA, Alinity I, ARCHITECT

BMS Entered into a Collaboration with GentiBio for the Development of New Treg Therapies Against Inflammatory Bowel Diseases

Published: Aug 12, 2022 | Tags: BMS, GentiBio, Treg Platform, Inflammatory Bowel Diseases, Pharma, Immunology, Autoimmune Diseases

Gamida Cell Reports First Patient Dosing in P-I/II Study of GDA-201 for the Treatment of Follicular and Diffuse Large B Cell Lymphoma

Published: Aug 10, 2022 | Tags: Gamida Cell, GDA-201, Follicular Lymphoma, Diffuse Large B Cell Lymphoma, Clinical Trials

Just-Evotec Biologics Expands its Partnership with Alpine Immune Sciences for the Commercial Process Development of ALPN-303 to Treat Systemic Lupus Erythematosus

Published: Aug 10, 2022 | Tags: Just-Evotec Biologics, Alpine Immune Sciences, ALPN-303, J.DESIGN, Systemic Lupus Erythematosus, Inflammatory Disease, Autoimmune Diseases, Pharma, P-I & P-II

Innovent’s Picankibart (IBI112) Meet its Primary Endpoint in the P-II (CIBI112A201) Study for the Treatment of Plaque Psoriasis

Published: Aug 10, 2022 | Tags: Innovent, Picankibart, IBI112, Plaque Psoriasis, Clinical trials, P-II, CIBI112A201 Study

AstraZeneca and Daiichi Sankyo Present P-Ib (TROPION-Lung02) Trial Results of Datopotamab Deruxtecan (Dato-DXd) for Advanced NSCLC at WCLC 2022

Published: Aug 10, 2022 | Tags: AstraZeneca, Daiichi Sankyo, Datopotamab deruxtecan, Dato-DXd, Advanced NSCLC, P-Ib TROPION-Lung02 Trial, WCLC, 2022

Merck Entered into a Multi-Year Strategic Research Collaboration with Cerevance to Discover Novel Targets Using NETSseq Technology for Alzheimer’s Disease

Published: Aug 10, 2022 | Tags: Merck, Cerevance, Novel Targets, Alzheimer’s Disease, Pharma

GSK Entered into an Option Agreement with Mersana to Co-Development and Commercialize XMT-2056 for the Treatment of Cancer

Published: Aug 10, 2022 | Tags: GSK, Mersana, XMT-2056, Cancer, HER2-expressing tumors, Pharma

Eli Lilly Reports the Availability of Taltz (ixekizumab) as New Citrate-Free Formulation to Reduce Injection Site Pain in the US

Published: Aug 8, 2022 | Tags: Eli Lilly, Taltz, ixekizumab, Citrate-Free Formulation, Injection Site Pain, Regulatory

HUTCHMED and AstraZeneca Report P-II (SAVANNAH) Trial Results of Tagrisso + Savolitinib for EGFR-Mutated NSCLC

Published: Aug 8, 2022 | Tags: HUTCHMED, AstraZeneca, Tagrisso, Savolitinib, EGFR-Mutated NSCLC, P-II SAVANNAH Trial

HUTCHMED Reports P-III (FRESCO-2) Trial Results of Fruquintinib for the Treatment of Metastatic Colorectal Cancer

Published: Aug 8, 2022 | Tags: HUTCHMED, Fruquintinib, Metastatic Colorectal Cancer, P-III, FRESCO-2 Trial

AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) Receive the US FDA’s Approval as First HER2-Directed Therapy for HER2-low Metastatic Breast Cancer

Published: Aug 8, 2022 | Tags: AstraZeneca, Daiichi Sankyo, Enhertu, trastuzumab deruxtecan, HER2-low Metastatic Breast Cancer, Regulatory, US, FDA, Approval

Genmab Expands its 2015 Agreement with BioNTech to Develop and Commercialize Novel Immunotherapy for Cancer

Published: Aug 8, 2022 | Tags: Genmab, BioNTech, Novel Immunotherapy, GEN1053, GEN1046, Cancer, HexaBody technology, Biotech

Myovant and Pfizer’s Myfembree Receive the US FDA’s Approval for the Treatment of Pain Associated with Endometriosis

Published: Aug 8, 2022 | Tags: Myovant Sciences, Pfizer, Myfembree, Pain, Endometriosis, Regulatory, US, FDA, Approval

Related Post: PharmaShots Weekly Snapshots (August 1 – 5, 2022)


Senior Editor

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions